Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company has marked a milestone with the start of its Phase 1 clinical trial for onCARlytics, a CD19 oncolytic virotherapy drug candidate. The trial, known as OASIS (Oncolytic Assessment and Safety in Solid Tumours), represents a world-first in clinical research, combining CD19 oncolytic virotherapy with a CD19 targeting bispecific monoclonal antibody, blinatumomab (Blincyto Amgen). The primary objective of the OASIS trial is to assess the safety and tolerability of onCARlytics (CF33-CD19) when administered intravenously or intratumorally in combination with blinatumomab.
Chong said: This is a milestone weve been eagerly anticipating, given the encouraging signs we have seen from the pre-clinical work performed to date.
We believe onCARlytics may provide a new solution for clinicians treating solid tumours that have previously been untreatable using CD19-targeting biological drugs, and we hope our technology can bring much needed relief to patients in want of new treatments.
I am particularly pleased with the speed at which our team drove the pre-clinical data from a novel therapy, into a Phase 1 trial in a little over two years, and reflects the enthusiasm for this promising therapy, from all involved.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/imugene-thrilled-as-first-patient-dosed-in-phase-1-oasis-trial-994115452
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Gio News UK journalist was involved in the writing and production of this article.